Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Upstream Bio, Inc. (UPB)
Company Research
Source: GlobeNewswire
– Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP – – Commenced startup for a Phase 2 clinical trial in COPD; on track for first patient to be dosed in H2 2025 – – Completed upsized IPO with gross proceeds of approximately $293 million, extending runway through 2027 – WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the third quarter ended September 30, 2024, and provided a summary of recent business highlights. “At Upstream Bio, we continue to make significant progress toward developing verekitug, the only monoclonal antibody currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, in severe respiratory diseases with substantial unmet needs. We expe
Show less
Read more
Impact Snapshot
Event Time:
UPB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UPB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UPB alerts
High impacting Upstream Bio, Inc. news events
Weekly update
A roundup of the hottest topics
UPB
News
- Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare ConferenceGlobeNewswire
- Upstream Bio, Inc. (NASDAQ: UPB) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $75.00 price target on the stock.MarketBeat
- Upstream Bio, Inc. (NASDAQ: UPB) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $38.00 price target on the stock.MarketBeat
- Upstream Bio, Inc. (NASDAQ: UPB) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.MarketBeat
- Upstream Bio, Inc. (NASDAQ: UPB) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
UPB
Sec Filings
- 11/8/24 - Form SEC
- 11/8/24 - Form SEC
- 11/7/24 - Form SC
- UPB's page on the SEC website